Frequently asked questions
Submitted by Anonymous (not verified) on 14 March 2025 - 13:00
Frequently asked questions
EMEA-002559-PIP09-23
Submitted by Anonymous (not verified) on 14 March 2025 - 12:52
EMEA-002559-PIP09-23
Frequently asked questions (FAQs): How to create, submit and withdraw a Clinical Trial Application - CTIS Training Programme - Module 10
Submitted by Anonymous (not verified) on 14 March 2025 - 12:46
Frequently asked questions (FAQs): How to create, submit and withdraw a Clinical Trial Application - CTIS Training Programme - Module 10
Opinion/decision on a Paediatric investigation plan (PIP): Litfulo, Ritlecitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0026/2024
Submitted by Anonymous (not verified) on 14 March 2025 - 12:34
Opinion/decision on a Paediatric investigation plan (PIP): Litfulo, Ritlecitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0026/2024
Opinion/decision on a Paediatric investigation plan (PIP): Sotyktu, Deucravacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0008/2024
Submitted by Anonymous (not verified) on 14 March 2025 - 12:09
Opinion/decision on a Paediatric investigation plan (PIP): Sotyktu, Deucravacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0008/2024
EMEA-002303-PIP01-17-M04
Submitted by Anonymous (not verified) on 14 March 2025 - 11:52
EMEA-002303-PIP01-17-M04
User guide for micro, small and medium-sized enterprises
Submitted by Anonymous (not verified) on 14 March 2025 - 11:40
User guide for micro, small and medium-sized enterprises
EMA Management Board: highlights of March 2025 meeting
Submitted by Anonymous (not verified) on 14 March 2025 - 11:30
EMA Management Board: highlights of March 2025 meeting
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 March 2025
Submitted by Anonymous (not verified) on 14 March 2025 - 11:00
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 March 2025
EMEA-002141-PIP01-17-M04
Submitted by Anonymous (not verified) on 14 March 2025 - 10:54
EMEA-002141-PIP01-17-M04